T1	Qualifier 12 25	decompensated
T2	Condition 26 39	liver disease
R1	Has_qualifier Arg1:T2 Arg2:T1	
T3	Measurement 41 47	Childs
T4	Value 48 51	B-C
R2	Has_value Arg1:T3 Arg2:T4	
T5	Scope 12 39	decompensated liver disease
T6	Scope 41 51	Childs B-C
R3	Subsumes Arg1:T5 Arg2:T6	
T7	Condition 54 79	hepato-cellular carcinoma
T8	Temporal 81 93	pre-existing
T9	Qualifier 94 100	severe
T10	Condition 101 111	depression
T11	Condition 121 140	psychiatric disease
T12	Qualifier 115 120	other
T13	Condition 154 169	cardiac disease
T14	Qualifier 142 153	significant
R4	Has_qualifier Arg1:T13 Arg2:T14	
T15	Qualifier 171 182	significant
T16	Condition 183 196	renal disease
R5	Has_qualifier Arg1:T16 Arg2:T15	
T17	Condition 198 215	seizure disorders
T18	Qualifier 219 225	severe
T19	Condition 226 237	retinopathy
R6	Has_qualifier Arg1:T11 Arg2:T12	
R7	Has_qualifier Arg1:T10 Arg2:T9	
*	OR T10 T11
T20	Scope 94 140	severe depression or other psychiatric disease
R8	Has_temporal Arg1:T20 Arg2:T8	
*	OR T7 T20 T5 T19 T18 T17 T16 T13
T21	Drug 249 260	telbivudine
T22	Procedure 268 285	antiviral therapy
R9	Subsumes Arg1:T22 Arg2:T21	
T23	Multiplier 303 316	more than one
T24	Condition 317 319	NA
*	OR T24 T23 T22
T25	Temporal 320 331	in the past
R10	Has_temporal Arg1:T24 Arg2:T25	
T26	Drug 343 353	interferon
T27	Drug 357 370	peginterferon
T28	Procedure 371 380	treatment
T29	Temporal 381 392	in the past
*	OR T27 T26
T30	Scope 343 370	interferon or peginterferon
R11	Has_scope Arg1:T28 Arg2:T30	
R12	Has_temporal Arg1:T28 Arg2:T29	
T31	Procedure 404 421	antiviral therapy
T32	Drug 430 449	systemic anti-viral
R13	AND Arg1:T31 Arg2:T32	
T33	Procedure 451 466;488 497	anti-neoplastic treatment
T34	Procedure 470 497	immuno-modulatory treatment
T35	Multiplier 509 531	supraphysiologic doses
T36	Drug 535 543	steroids
T37	Procedure 548 557	radiation
R14	Has_multiplier Arg1:T36 Arg2:T35	
R15	Has_multiplier Arg1:T37 Arg2:T35	
*	OR T36 T37
T38	Scope 509 557	supraphysiologic doses of steroids and radiation
*	OR T33 T34 T31
T39	Scope 404 497	antiviral therapy for any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment
R16	Subsumes Arg1:T39 Arg2:T38	
T40	Temporal 559 583	within the past 6 months
R17	Has_temporal Arg1:T39 Arg2:T40	
T41	Value 586 594	Positive
T42	Measurement 595 599;613 625	test for anti-HIV
T43	Measurement 595 599;613 616;627 635	test for anti-HCV
*	OR T43 T42
T44	Temporal 600 612	at screening
T45	Scope 595 599;613 635	test for anti-HIV, anti-HCV
R18	Has_value Arg1:T45 Arg2:T41	
R19	Has_temporal Arg1:T45 Arg2:T44	
T46	Mood 655 671	expected to need
T47	Procedure 672 698	systemic antiviral therapy
R20	Has_mood Arg1:T47 Arg2:T46	
T48	Temporal 737 788	at any time during their participation in the study
R21	Has_temporal Arg1:T47 Arg2:T48	
T49	Reference_point 756 788	their participation in the study
R22	Has_index Arg1:T48 Arg2:T49	
T50	Drug 872 881	acyclovir
T51	Multiplier 843 850;862 868	limited course
T52	Multiplier 852 860	<=7 days
R23	Subsumes Arg1:T51 Arg2:T52	
R24	Has_multiplier Arg1:T50 Arg2:T51	
T53	Condition 886 902	herpetic lesions
T54	Temporal 903 967	more than 1 month prior to the first administration of test drug
T55	Reference_point 930 967	the first administration of test drug
R25	Has_index Arg1:T54 Arg2:T55	
T56	Mood 972 984	not excluded
R26	AND Arg1:T50 Arg2:T53	
R27	Has_temporal Arg1:T50 Arg2:T54	
R28	Has_mood Arg1:T50 Arg2:T56	
T57	Negation 808 817	Exception
R29	Has_negation Arg1:T50 Arg2:T57	
T58	Measurement 987 1008	Serum total bilirubin
T59	Value 1009 1044	> 3 times the upper limit of normal
R30	Has_value Arg1:T58 Arg2:T59	
T60	Temporal 1045 1057	at screening
R31	Has_temporal Arg1:T58 Arg2:T60	
T61	Condition 1089 1097	bleeding
T62	Condition 1103 1121	esophageal varices
R32	AND Arg1:T61 Arg2:T62	
T63	Qualifier 1125 1130	other
T64	Condition 1131 1185	conditions consistent with decompensated liver disease
R33	Has_qualifier Arg1:T64 Arg2:T63	
*	OR T61 T64
T65	Condition 1219 1236	medical condition
T66	Condition 1253 1274	chronic liver disease
R34	AND Arg1:T65 Arg2:T66	
T67	Negation 1275 1285	other than
T68	Condition 1286 1289	HBV
R35	Has_negation Arg1:T68 Arg2:T67	
T69	Scope 1275 1289	other than HBV
T70	Condition 1297 1312	hemochromatosis
T71	Condition 1314 1334	autoimmune hepatitis
*	OR T71 T70 T72
T72	Condition 1336 1360	metabolic liver diseases
T73	Condition 1371 1379	Wilson's
T74	Condition 1384 1413	alpha1-antitrypsin deficiency
T75	Condition 1415 1438	alcoholic liver disease
T76	Condition 1440 1455	toxin exposures
T77	Condition 1457 1468	thalassemia
*	OR T77 T76 T75 T73 T74
T78	Scope 1371 1468	Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia
R36	Subsumes Arg1:T72 Arg2:T78	
T79	Scope 1297 1468	hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson's and alpha1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia
R37	Subsumes Arg1:T69 Arg2:T78	
R38	AND Arg1:T65 Arg2:T68	
T80	Person 1472 1477	Women
T81	Condition 1491 1500	pregnancy
T82	Temporal 1483 1490	ongoing
R39	Has_temporal Arg1:T81 Arg2:T82	
T83	Observation 1512 1526	breast feeding
*	OR T83 T81
T84	Measurement 1529 1545	Neutrophil count
T85	Value 1546 1561	<1500 cells/mm3
R40	Has_value Arg1:T84 Arg2:T85	
T86	Measurement 1565 1579	platelet count
T87	Value 1580 1597	<90,000 cells/mm3
R41	Has_value Arg1:T86 Arg2:T87	
T88	Temporal 1598 1610	at screening
*	OR T84 T86
T89	Scope 1529 1597	Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3
R42	Has_temporal Arg1:T89 Arg2:T88	
T90	Measurement 1613 1623	Hemoglobin
T91	Value 1624 1635	< 11.5 g/dL
T92	Person 1640 1647	females
T93	Value 1652 1663	< 12.5 g/dL
T94	Person 1668 1671	men
T95	Temporal 1672 1684	at screening
A1	Optional T92
A2	Optional T94
R43	Has_value Arg1:T92 Arg2:T91	
R44	Has_value Arg1:T94 Arg2:T93	
*	OR T92 T94
T96	Scope 1624 1671	< 11.5 g/dL for females and < 12.5 g/dL for men
R45	Has_scope Arg1:T90 Arg2:T96	
R46	Has_temporal Arg1:T90 Arg2:T95	
T97	Measurement 1687 1709	Serum creatinine level
T98	Value 1710 1722	>120 umol/ml
T99	Person 1727 1730	men
T100	Value 1735 1747	>105 umol/ml
T101	Person 1752 1757	women
A3	Optional T101
A4	Optional T99
R47	Has_value Arg1:T101 Arg2:T100	
R48	Has_value Arg1:T99 Arg2:T98	
T102	Temporal 1758 1770	at screening
T103	Scope 1710 1757	>120 umol/ml for men and >105 umol/ml for women
R49	Has_scope Arg1:T97 Arg2:T103	
R50	Has_temporal Arg1:T97 Arg2:T102	
T104	Condition 1791 1810	psychiatric disease
T105	Qualifier 1784 1790	severe
R51	Has_qualifier Arg1:T104 Arg2:T105	
T106	Condition 1823 1833	depression
R52	Subsumes Arg1:T104 Arg2:T106	
T107	Qualifier 1835 1841	Severe
T108	Condition 1842 1861	psychiatric disease
T109	Condition 1876 1892	major depression
T110	Condition 1896 1905	psychosis
T111	Procedure 1919 1928	treatment
T112	Drug 1937 1962	antidepressant medication
T113	Drug 1966 1984	major tranquilizer
T114	Multiplier 1988 2005	therapeutic doses
T115	Condition 2010 2020	depression
T116	Condition 2024 2033	psychosis
T117	Temporal 2034 2055	for at least 3 months
T118	Condition 2059 2075	suicidal attempt
T119	Procedure 2077 2092	hospitalization
T120	Condition 2097 2116	psychiatric disease
R53	AND Arg1:T119 Arg2:T120	
T121	Condition 2133 2143	disability
T122	Condition 2153 2172	psychiatric disease
R54	AND Arg1:T121 Arg2:T122	
*	OR T113 T112
T123	Scope 1937 1984	antidepressant medication or major tranquilizer
R56	Has_multiplier Arg1:T123 Arg2:T114	
R57	Has_temporal Arg1:T116 Arg2:T117	
R58	Has_scope Arg1:T111 Arg2:T123	
R55	AND Arg1:T111 Arg2:T115	
*	OR T110 T109 T121 T119 T118 T116 T111
T124	Scope 1876 2172	major depression or psychosis, a period of treatment with an antidepressant medication or major tranquilizer at therapeutic doses for depression or psychosis for at least 3 months, a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease
*	OR T108 T107
T125	Scope 1835 1861	Severe psychiatric disease
R59	Subsumes Arg1:T125 Arg2:T124	
T126	Scope 1784 1833	severe psychiatric disease, especially depression
R60	Subsumes Arg1:T126 Arg2:T125	
T127	Condition 2226 2252	inflammatory bowel disease
T128	Condition 2186 2218	immunologically mediated disease
T129	Condition 2254 2289	idiopathic thrombocytopenic purpura
T130	Condition 2291 2310	lupus erythematosus
T131	Condition 2312 2339	autoimmune hemolytic anemia
T132	Condition 2341 2352	scleroderma
T133	Qualifier 2354 2360	severe
T134	Condition 2361 2370	psoriasis
R61	Has_qualifier Arg1:T134 Arg2:T133	
T135	Condition 2372 2392	rheumatoid arthritis
*	OR T130 T129 T127 T135 T134 T132 T131
T136	Scope 2226 2392	inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis
R62	Subsumes Arg1:T128 Arg2:T136	
T137	Condition 2425 2450	chronic pulmonary disease
T138	Condition 2467 2488	functional limitation
R63	AND Arg1:T137 Arg2:T138	
T139	Qualifier 2490 2496	Severe
T140	Condition 2497 2512	cardiac disease
R64	Has_qualifier Arg1:T140 Arg2:T139	
T141	Measurement 2520 2524	NYHA
T142	Value 2525 2551	Functional Class III or IV
T143	Condition 2553 2574	myocardial infarction
T144	Temporal 2575 2590	within 6 months
R65	Has_temporal Arg1:T143 Arg2:T144	
T145	Condition 2592 2620	ventricular tachyarrhythmias
T146	Temporal 2631 2638	ongoing
T147	Procedure 2639 2648	treatment
R66	Has_temporal Arg1:T147 Arg2:T146	
R67	AND Arg1:T145 Arg2:T147	
T148	Condition 2650 2665	unstable angina
T149	Qualifier 2669 2674	other
T150	Qualifier 2675 2686	significant
T151	Condition 2687 2710	cardiovascular diseases
R68	Has_qualifier Arg1:T151 Arg2:T150	
R69	Has_qualifier Arg1:T151 Arg2:T149	
*	OR T148 T151 T145 T143 T141
R70	Has_value Arg1:T141 Arg2:T142	
T152	Scope 2490 2512	Severe cardiac disease
T153	Scope 2520 2710	NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases
R71	Subsumes Arg1:T152 Arg2:T153	
T154	Qualifier 2727 2733	severe
T155	Condition 2734 2750	seizure disorder
T156	Drug 2762 2776	anticonvulsant
T157	Temporal 2754 2761	current
R72	Has_temporal Arg1:T156 Arg2:T157	
R73	Has_qualifier Arg1:T155 Arg2:T154	
*	OR T156 T155
T158	Temporal 2798 2804	active
T159	Mood 2808 2817	suspected
T160	Condition 2818 2824	cancer
*	OR T159 T158
T161	Scope 2798 2817	active or suspected
R74	Has_scope Arg1:T160 Arg2:T161	
T162	Condition 2841 2851	malignancy
T163	Measurement 2862 2880	risk of recurrence
T164	Value 2884 2904	>=20% within 2 years
R75	Has_value Arg1:T163 Arg2:T164	
R76	AND Arg1:T162 Arg2:T163	
T165	Condition 2922 2928	lesion
T166	Mood 2929 2939	suspicious
T167	Condition 2943 2961	hepatic malignancy
R77	Has_mood Arg1:T167 Arg2:T166	
R78	AND Arg1:T165 Arg2:T167	
T168	Procedure 2967 2990	screening imaging study
T169	Measurement 3020 3043	likelihood of carcinoma
T170	Value 3047 3052	<=10%
R79	Has_value Arg1:T169 Arg2:T170	
R80	AND Arg1:T165 Arg2:T168	
T171	Scope 2922 2990	lesion suspicious of hepatic malignancy on a screening imaging study
A5	Optional T171
R81	AND Arg1:T171 Arg2:T169	
*	OR T160 T162
T172	Qualifier 3122 3130	systemic
T173	Procedure 3131 3146;3189 3198	anti-neoplastic treatment
T174	Procedure 3172 3198	immunomodulatory treatment
T175	Procedure 3158 3167	radiation
R82	Subsumes Arg1:T173 Arg2:T175	
T176	Qualifier 3210 3218	systemic
T177	Drug 3219 3234	corticosteroids
R83	Has_qualifier Arg1:T177 Arg2:T176	
*	OR T173 T174
T178	Scope 3131 3235	anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids)
R84	Has_qualifier Arg1:T178 Arg2:T172	
R85	Subsumes Arg1:T174 Arg2:T177	
T179	Temporal 3236 3284	<=6 months prior to the first dose of study drug
T180	Reference_point 3256 3284	the first dose of study drug
R86	Has_index Arg1:T179 Arg2:T180	
R87	Has_temporal Arg1:T178 Arg2:T179	
T181	Mood 3292 3303	expectation
T182	Procedure 3314 3323	treatment
T183	Mood 3324 3338	will be needed
R88	Has_mood Arg1:T182 Arg2:T181	
R89	Has_mood Arg1:T182 Arg2:T183	
T184	Temporal 3339 3367	at any time during the study
R90	Has_temporal Arg1:T182 Arg2:T184	
*	OR T178 T182
T185	Procedure 3370 3397	Major organ transplantation
T186	Condition 3400 3415	Thyroid disease
T187	Measurement 3421 3437	thyroid function
T188	Value 3438 3455	poorly controlled
R91	Has_value Arg1:T187 Arg2:T188	
R92	AND Arg1:T186 Arg2:T187	
T189	Qualifier 3456 3481	on prescribed medications
R93	Has_qualifier Arg1:T187 Arg2:T189	
T190	Value 3497 3505	abnormal
T191	Measurement 3506 3533	thyroid stimulating hormone
T192	Measurement 3537 3554	T4 concentrations
*	OR T191 T192
T193	Scope 3497 3554	abnormal thyroid stimulating hormone or T4 concentrations
R94	Has_value Arg1:T193 Arg2:T190	
T194	Scope 3497 3554	abnormal thyroid stimulating hormone or T4 concentrations
T195	Measurement 3574 3606	antibodies to thyroid peroxidase
T196	Value 3561 3570	elevation
R95	Has_value Arg1:T195 Arg2:T196	
T197	Condition 3615 3657	clinical manifestations of thyroid disease
*	OR T195 T197 T193
T198	Qualifier 3702 3708	severe
T199	Condition 3709 3720	retinopathy
R96	Has_qualifier Arg1:T199 Arg2:T198	
T200	Condition 3727 3740	CMV retinitis
T201	Condition 3742 3761	macula degeneration
*	OR T200 T201
T202	Scope 3727 3761	CMV retinitis, macula degeneration
T203	Scope 3702 3720	severe retinopathy
R97	Subsumes Arg1:T203 Arg2:T202	
T204	Qualifier 3766 3785	clinically relevant
T205	Condition 3786 3811	ophthalmological disorder
T206	Condition 3819 3836	diabetes mellitus
T207	Condition 3840 3852	hypertension
*	OR T206 T207
T208	Scope 3819 3852	diabetes mellitus or hypertension
R98	Has_scope Arg1:T205 Arg2:T208	
*	OR T205 T204 T203
T209	Post-eligibility 3854 3951	Inability or unwillingness to provide informed consent or abide by the requirements of the study.
T210	Post-eligibility 3953 4112	History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
T211	Measurement 4139 4156	alpha-fetoprotein
T212	Value 4157 4167	>100 ng/mL
R99	Has_value Arg1:T211 Arg2:T212	
T213	Temporal 4249 4279	at least the previous 3 months
T214	Reference_point 4258 4279	the previous 3 months
R100	Has_index Arg1:T213 Arg2:T214	
T215	Condition 4189 4198	stability
T216	Value 4200 4213	less than 10%
T217	Measurement 4214 4222	increase
R101	Has_value Arg1:T217 Arg2:T216	
T218	Scope 4200 4222	less than 10% increase
R102	Subsumes Arg1:T215 Arg2:T218	
R103	Has_temporal Arg1:T215 Arg2:T213	
T219	Negation 4182 4188	unless
R104	Has_negation Arg1:T215 Arg2:T219	
T220	Condition 4306 4319	alcohol abuse
T221	Condition 4294 4298;4314 4319	drug abuse
*	OR T220 T221
T222	Multiplier 4321 4328	20g/day
T223	Multiplier 4341 4348	30g/day
T224	Person 4353 4356	men
T225	Person 4333 4338	women
*	OR T222 T223
R105	AND Arg1:T222 Arg2:T225	
R106	AND Arg1:T223 Arg2:T224	
T226	Scope 4321 4356	20g/day for women & 30g/day for men
R107	Subsumes Arg1:T220 Arg2:T226	
T227	Post-eligibility 4360 4472	Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening
T228	Condition 4495 4511	hypersensitivity
T229	Drug 4515 4525	interferon
R108	AND Arg1:T228 Arg2:T229	
